Abstract

To evaluate the clinical efficacy of Beifuxin in the management of surgical difficult-to-heal wounds. Our hospital enrolled 122 patients challenging with wound healing between June 2022 and June 2023, categorizing them randomly into a trial group and a control group. Treatment with Beifuxin was provided to the observation group, while the control group was managed with traditional wound dressing approaches. Comparative analysis was conducted between the two groups regarding clinical effectiveness, recovery duration, granulation tissue appearance, skin quality restoration, recurrence frequency and infection rate. The observation group displayed a notably higher total clinical effectiveness rate of 93.33 % in contrast to the 73.33 % rate in the control group, coupled with quicker wound healing and earlier onset of granulation tissue. Compared with the control group, the observation group displayed healed wounds with color, tension and hardness approaching that of normal skin, alongside lower rates of recurrence and wound infection. In managing difficult-to-heal wounds, Beifuxin has exhibited substantial clinical efficacy, fostering advanced wound healing, encouraging granulation tissue formation and enhancing the overall wound healing quality. Beifuxin exhibits potential for promising clinical applications and merits further comprehensive research and implementation.